(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
about
Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IVPharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteersPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisThe pharmacological landscape and therapeutic potential of serine hydrolasesLixisenatide as add-on therapy to basal insulinInvolvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formationDesign and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitorsAnagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactionsDipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstructionPharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assaysIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extractsTissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic miceScreening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4.Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes.An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Emerging principles in protease-based drug discovery.Emerging treatment options for type 2 diabetesA potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.The role of incretins in glucose homeostasis and diabetes treatment.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndromeDipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic ratsThe metabolic serine hydrolases and their functions in mammalian physiology and disease.Design, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.
P2860
Q24543939-DB89E860-234D-4BE4-87F7-F86894CAE846Q24658008-DDA09653-E930-4966-8287-8E2A38F5DDD0Q26749524-89715C47-17AA-481C-99D9-DDAB903A3618Q26778329-68672E40-6A09-414D-961E-4F5C81ECB377Q26795473-1EB98043-2ABF-4EAC-8DBE-D2C14A984A54Q26995817-B1AB4BFB-8503-45D0-80D6-61EF8DD945D6Q27007547-C4D34162-4B9C-49FF-86C8-77F3A25123DEQ27649728-AB175B8F-359D-42D4-AB21-7228EA1551EDQ27684616-14EBF7AC-0DAB-4C83-B665-2C4962B9FBECQ27701492-9ABFEE31-C4B3-4F4C-88A9-8875F0A40654Q28237208-CF71577F-01E7-4C56-8A10-CC5CD781BBC1Q28252893-3795C9F5-B60F-43FA-AA0C-95B31966ADEFQ28483681-747D0E0F-E843-4436-A533-9471EEF951ADQ28483936-BEFE7D26-7125-4B02-A1CC-8050748A8D9FQ31036099-5158735F-C709-480C-B72F-C180ADF3E19BQ33237060-7A9FE4DD-1328-4B0A-87B0-2F487EF994CBQ33428789-F460518A-661A-41A4-9145-77989CAF03DEQ33482122-00A8ED80-ECFB-4086-BE09-34D608E0424FQ33603301-4F71089E-3568-4F11-8795-CE667BE51859Q33671491-B77B4DD3-B2AB-4371-A628-C6CED8F31373Q33930280-55852A8D-DDBF-418D-BBEC-47646E7B5CF7Q34016283-BD56F436-6F2F-40D8-B657-74B0DD4A0E94Q34019325-6374CCC3-C7D5-4A4E-B0C4-9068A565AE19Q34063707-CC629E28-DAEA-45E6-B00A-9BE879FFEA37Q34190368-5266636A-898C-4D66-847F-6CB6B5AB1F96Q34219918-27BE99A8-7092-4EF5-85C9-3163A8922F4BQ34278297-C3591C82-D8C0-4482-ACD6-5F9663605E23Q34282102-FFFA1434-133F-412A-874E-C7E13E43C52CQ34381281-9E764A2C-9E1E-47D6-822D-2EFA9B800014Q34441309-5060920B-51DD-412B-A9DF-6AF5C2A33893Q34563154-C85CE561-5390-45A9-8C56-16A9945BD957Q34569365-35F794DF-FB6A-4FF1-B4EB-43E1045C32B0Q34638128-36C48B09-77C0-40E2-BA9D-F6E6D435E3FBQ34718822-900727EA-26D2-4425-BA6C-D8FF116C1CC3Q34901533-1D921E26-E87A-4DA6-B779-762A21B24C67Q35087846-0B11731F-36CF-4B55-9CC9-A41317D1E411Q35141322-A0E4B8F2-11FC-4625-90B4-98EF93441A60Q35193875-EB571CDD-5196-48B0-9D4E-B0C84E184A74Q35333042-20BDB155-BC66-4B0E-8F44-BC722A6D3F1CQ35615176-699A7B13-2933-4FA2-96BA-CAA2EBDD4579
P2860
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@en
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@nl
type
label
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@en
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@nl
prefLabel
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@en
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@nl
P2093
P356
P1476
(2R)-4-oxo-4-[3-(trifluorometh ...... treatment of type 2 diabetes.
@en
P2093
Aleksandr Petrov
Ann E Weber
Barbara Leiting
Bei B Zhang
Dooseop Kim
Frank Marsilio
George J Eiermann
Gerard J Hickey
Giovanna Scapin
Huaibing He
P304
P356
10.1021/JM0493156
P407
P577
2005-01-01T00:00:00Z